strong tavr perform despit guid adjust
posit reimburs test volum updat
structur high cut pt
updat learn expect unexpect
ndr takeaway oraxol submiss track ak
underappreci potenti sourc
underappreci revenu opportun initi outperform
maintain sight object group meet
read elect test reduct april
posit outlook rebound
analyst certif import disclosur see
quick take
indivum materi impact revenu
larg new custom past month
hospit cfo survey impact
survey urologist appear keen jelmyto lg utuc
look competit
new clinic collabor merck head neck cancer
burn offer shelter covid storm vitiligo outpati
drive lt outlook initi pt
pre-releas in-lin detail cash-conserv effort
strong phase reveal hypoparathyroid reiter outperform
pt
highlight qualiti fundament biotech name
tukysa approv broad use brain metastasi no-brain
clinic trial tracker week end
caught compani call longer-than-usu prepar remark kept number analyst ask
question bullishli ew benefit unusu order pattern compani mostli consign
sale dont see much quarter-end ship bulk deal edward also note unusu inventori channel
demur market share detail highlight product support clinic data sapien
paravalvular leak ultra shorter procedur time drive strong result visibl patient funnel alway
challeng depend patient show screen especi tricki
top stori week report earn street consensu covid pandem began impact
volum late admiss growth fell january/februari second half march
april cut cost remain hope state re-open economi near futur due
lack visibl compani remov ebitda ep guidanc previous
sale exceed our/street estim core sale grow cc ep
beat our/street higher sale om lower tax management note similar
direct trend across countries/timelin messag overal firm gross impact
within guidanc apac impact less expect china show improv us/emea
headwind pick march management withdrew guidanc given high uncertainti though note core
growth februari high end prior guidanc underli upsid partial off-set also
highlight multipl operating-expens reduct effort includ furlough program reduc amount time work
solid
strong tavr perform despit guid adjust expect recoveri
edward report rev line consensu ahead recent revis estim
biggest surpris quarterli number tavr revenu y/i ahead consensus/our estim
respect guidanc lower bracket consensus/
estim respect impact seen sever gradual recoveri
close ew origin expect tweak estim slightli reflect compani guidanc maintain
fundament posit stanc name howev edward strong perform stark departur med-tech
compani space ask
part pasadena studi prasinezumab patient earli parkinson diseas miss primari endpoint
prove suffici safe well toler efficaci signal secondari endpoint move part partner roch
work clinic activ plan determin futur studi base analysi data part detail
part result present futur medic meet includ secondari efficaci endpoint exploratori clinic
endpoint suspect durat part may long enough activ arm clinic separ
placebo part contain control arm patient receiv month treatment similar ppmi
posit reimburs test volum updat structur high cut pt
idxg report financi expect pre-announc revenu outlook disclos april
busi trend gener line slightli better recent data point clinic diagnost compani
encourag investor segment updat two theme progress restructur includ integr juli
acquisit pharma servic unit execut commerci clinic diagnost stori restructur move
slowli forecast compani take charg revenu second quarter row limit
tangibl evid reduct cost structur view necessari acceler path profit convers
clinic test volum increas y-o-i despit march slowdown
updat learn expect unexpect
solid perform featur updat highlight effort submit regulatori file aducanumab
commentari fell short expect despit wide recogn complex disrupt mix registr
dataset impact pandem result believ aducanumab bla submiss roll
modul file complet expect base aducanumab track design suspect fda may
conduct roll review process conclud noth typic aducanumab file process make futil
predict mileston posit side subtl signal recept encourag come fda base
today updat updat estim maintain outperform detail insid
ndr takeaway oraxol submiss track ak underappreci potenti
spoke manag recent investor meet takeaway includ oral paclitaxel encequidar oraxol
track fda file expect broad label taxane-elig metastat breast cancer regardless prior therapi
addit surviv data phase studi expect low risk extend review oraxol
prefer fund launch partner nondilut structur rather equiti believ manag made
strong case clinic relev comparison iv dose phase breast cancer studi still soc
indic outsid breast cancer pk/pd comparison iv paclitaxel clinic relev potenti futur use
lung ovarian cancer
underappreci revenu opportun initi outperform
initi coverag inc outperform rate price target believ base busi
strateg partnership provid potenti near-term revenu clinic valid proprietari technolog platform
posit compani fund emerg pipelin evolv partnership-bas busi model one
wholly-own asset partner launch next month could includ osteoporosi
hematolog infectious-diseas vaccin believ revenu potenti fulli reflect current trade
level note catalyst next month includ potenti registration-en data
potenti launch longer term believ manag may opt select invest wholly-
own asset gener organ growth
bionano announc agreement largest us fshd test lab univers iowa hospit
clinic use saphyr-bas test fshd patient fshd rel small market agreement
provid anoth data point grow accept bngo saphyr optic imag prefer platform detect
larg genom rearrang amen sequencing-bas technolog view fshd replac
labor-intens blot saphyr-bas test potenti faster turnaround time improv accuraci
detect repeat continu expect data multipl valid studi drive demand clinic
cytogenet test saphyr begin
yesterday close provid latest thought impact overal busi updat
larg line manag prior commentari pandem virtual confer
provid detail around growth impact base geograph growth rate provid impli recent y/i
declin similar johnson johnson jnj-nyse cover recent note medic devic
busi rang growth impact exclud neg effect typic fiscal year-end larg
order custom priorit cash reduc product inventori manag indic overal world-wide impact
compani busi similar magnitud declin report med-tech compani month
feb china/apac march europe/u forward-look estim around sector
compani note slow recoveri seen china procedur expect signific expens de-lever
 salesforc among invest still made previous written believ solid
balanc sheet/cash flow convers support challeng near-term end-market compani pipelin
numer driver focu medium/long-term
maintain sight object group meet takeaway
host digit ndr apelli manag provid key takeaway focu
view manag confid timelin ga defin call given prior concern
intensifi pandem vulner studi popul addit path registr pegcetacoplan
pnh expect file remain favor regulatori strateg updat expect later quarter
given clear rel unchang setup near-regustr file pnh late-stag ga program well
emerg pipelin option continu view high-qual smid-cap biotech name stay bullish
read elect test reduct april posit outlook rebound
disclos revenu vs estim reduct cologuard volum first day
april stabil april level plan reduc spend salari cut furlough net
reduct april line anecdot data point receiv compani exposur
elect procedur expect nearli compani curtail spend magnitud reduct
larger anticip revis forecast call net loss roughli line prior forecast aggress cost cut
protect balanc sheet march cash balanc reduc pt account slower sale
report adj ebitda/ep well opco/street estim
respect covid pandem began impact last two week admiss growth declin
approxim end march april april impact even sever inpati
surgeri outpati surgeri compani see potenti declin start revers
state open visibl around time remain unclear result remov ebitda ep
guidanc previous respect due covid impact slash estim
price target
global pandem evolv seen greater rang modal target initi anti-vir
immune-modul agent vaccin need address morbid mortal sever patient categori
infect grow also better understand cours diseas especi hospit set
investor ascrib potenti upsid commercial/clin asset previous incorpor
valuat caution earli process understand viru elucid treatment hope
erad
highlight agent develop
today atyr life announcedth fda accept ind applic evalu patient sever
respiratori complic current phase patient pulmonari sarcoidosi interstiti lung diseas whose
inflammatori lung injuri might manifest similarli sever patient also believ moa align well
treat patient given abil reduc neutrophil infiltr shown preclin acut lung inuri
model specif lung
still wait clinic efficaci data second interim readout pulmonari sarcoidosi
believ first interim data safeti readout announc late last year provid support fda green light phase
studi
await updat atyr detail around recruitment/protocol believ rigor robust trial design
random double-blind placebo-control could serv well potenti acceler pathway approv opinion although
primari endpoint focu fever acut symptoms/sign could potenti secondary/exploratori endpoint
cover diseas manifest share variou categori ild short breath cough biomark measur
disclos skint revenu vs estim skint volum
paid case vs estim salari reduct employe less concern
volum revenu miss given small case volum disrupt impli revenu per paid case
vs forecast compani treat smaller wound believ lower price
per case reflect market dynam requir long-term revis econom assumpt skint posit
chronic wound market lower higher volum implement econom model requir signific reduct
 beyond level outlin today view
host key opinion leader cytomegaloviru cmv dr manish sagar discuss potenti
prophylact vaccin prevent cmv infect replay/transcript avail upon request dr
sagar infecti diseas specialist mainli treat adult cmv patient hospit also see pediatr cmv
patient commun center walk away call sever key takeaway develop
reason base cmv diseas manifest although broad test routin adopt present
rate limit step term cost robust get approv avail efficacy/safeti data
look promis howev sever question regard trial size durabl etc still remain phase studi could
potenti address upcom phase data enrol complet ahead plan current
phase studi first interim readout expect stay bullish
quick take
report adjust ebitda/ep well opco/street estim
respect although impact last two week impact clearli felt immedi adj
admiss declin averag even tell declin o/p-surgeri averag
i/p base calcul adj admiss normal prior mid-march estim
adj admiss growth would last two week march manag took number
measur address weak includ reduc salaries/cap-ex withdraw dividend suspend buyback
take revolv surprisingli due uncertainti remov ebitda ep guidanc previous
respect
indivum materi impact revenu larg new custom past month
disclos agreement privat held indivum view provid least non-va
revenu support strateg object diversifi revenu beyond va relationship pharma compani
expect non-va revenu face headwind least due disrupt
cautious optimist agreement indivum german biorespositori store tumor sampl may help cushion
near-term slowdown base convers manag believ indivum one new larg
pharma agreement disclos compani call believ sign least three new larg
custom past six month
updat model ahead result includ jakafi sale outlook amid ruxolitinib trial
cytokin storm pemazyr approv potenti label expans dermatolog buildout nda expect
tafasitamab opportun pdufa date pemazyr pemigatinib approv fda ahead
pdufa date prioriti review label indic pemazyr cca base orr
month dor studi uc readout expect on-going could serv
approv set could expand tumor-agnost set plan virtual launch note
minim impact updat model drive pt
hospit cfo survey impact
conduct survey chief financi offic us hospit april regard impact
hospit oper financ despit on-going pandem survey garner respons
number hot-spot state rang hospit size expect key take-away messag survey one
caution procedur capit spend hospit margin note survey snapshot current time
intend sequel month time gaug sentiment potenti impact univers particular
name coverag
survey urologist appear keen jelmyto lg utuc
conduct survey us urolog oncologist gain insight jelmyto adopt follow upcom june
launch physician sampl consist express enthusiasm incorpor jelmyto lg utuc treatment
paradigm averag expect use patient w/newli diagnos recurr diseas
time respect would consid patient see inelig caution sale
like slow gather steam current environ w/temporari miscellan j-code interpret
survey result support estim beyond w/minor revis pt remain unchang
also updat model current nmibc timelin
look competit
bmy/exel announc top-lin result rcc nivolumab cabozantinib beat sunitinib
median follow-up month data present upcom meet dataset
key return growth rcc view dataset strongest limit dataset within rcc combin exhibit
see insid previous rcc growth stunt introduct keytruda inlyta seem competit
increas market model model greater cabo use vs prior us rcc sale increas pt
result bode well addit combo
new clinic collabor merck head neck cancer
monday announc clinic collabor merck evalu combin keytruda novel
treatment hpv recurrent/metastat head neck cancer r/m hnscc new trial focu patient
previous expos checkpoint inhibitor part cue larger develop strategi
span early- late-lin set hpv-driven cancer combin studi dub run
parallel on-going phase monotherapi studi r/m hnscc per term drug suppli agreement
retain complet control news flow combin studi given translat result monotherapi track
readout reiter outperform rate pt
burn offer shelter covid storm vitiligo outpati drive lt outlook initi pt
initi coverag rcel outperform rate price target base continu recel adopt burn
market expect success clinic trial recel treatment vitiligo trauma wound data
expand address market support recel sale opportun pivot pipelin biotech
cell therapi invest thesi assum clinic data manufactur know-how serv potent long-term barrier
entri autolog cell therapi product recel furthermor view expans outpati set offer
potenti upsid obstacl rcel commerci model view secur uniqu outpati reimburs
code next month critic mileston
pre-releas in-lin detail cash-conserv effort
open sskn pre-releas revenu vs estim consensu guidanc
recur revenu expect estim match guidanc
xtrac recur instal base rose domest intern total gross procedur
revenu declin y/i march though treatment continu primarili non-lockdown state
domest clinics/treat continu april though visibl insuffici provid guid orders/
shipment resum wuhan china south korea cash-conserv effort furlough discretionari
spend vendor action total sale market clinic patient outreach webinar particip
date sskn also appli sba loan
strong phase reveal hypoparathyroid reiter outperform pt
four-week phase result clearli illustr transcon pth true replac therapi patient
hypoparathyroid arm highest dose met primari secondari composit
endpoint patient therein abl elimin standard care activ vitamin
supplement calcium safeti toler unremark continu open-label extens
see six-month data next quarter phase start follow regulatori discuss current data may well
enabl fda breakthrough design rais pt increas likelihood success transcon pth
view platform valid de-risk earlier pipelin program recommend investor purchas asnd share
highlight qualiti fundament biotech name
highlight potenti out-performance vs nbi index ytd view
particularli import year obvious gener cliff treprostinil franchis unlik happen
therefor see consensu sales/earn estim low stock still cheap less obviou
catalyst line orenitram freedom-ev label expans launch on-going remun pump track
launch tret dpi inhal data readout file tyvaso ph-ild label expans snda
potenti catalyst-rich also line tyvaso ph-ild remodulin isr tret pump launch
tukysa approv broad use brain metastasi no-brain
tukysa tucatinib approv well ahead august pdufa fda tukysa breakthrough therapi design
local advanc metastat breast cancer bc review real-tim oncolog review
program pivot data present sabc importantli one program
exclud brain metastasi patient adv mbc patient tucatinib post hr os
tucatinib compound proven brain-met efficaci believ adopt potenti nccn guidelin may
ventur beyond enrol criteria inde fda grant broader expect label includ exhibit increas
monotherapi opportun increas pt prior remain excit tv
clinic trial tracker week end
updat analysi clinic trial identifi new area focu potenti medic advanc
impress rapid expans number trial type intervent divers sponsor
geographi investor stay focus macro factor drive broader market dynam believ clinic trial trend
provid insight effort made stem tide especi interest studi
antivir approach provid direct therapeut intervent viru believ
drug success could provid immedi impact largest number patient recent host call
virolog drug develop expert dr brett korba replay ceo dr jay luli replay captur insight
april call dr scott gottlieb
may oppenheim med-tech day san francisco ca
may biotech summit featur chemistri life process institut
sept fall summit focus specialti pharma diseas gene therapi new york ny
oct houston oncolog summit md anderson cancer center
healthcar provid manag
